Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
11.5M
-
Number of holders
-
37
-
Total 13F shares, excl. options
-
2.99M
-
Shares change
-
-43.7K
-
Total reported value, excl. options
-
$9.02M
-
Value change
-
-$190K
-
Put/Call ratio
-
0.36
-
Number of buys
-
10
-
Number of sells
-
-13
-
Price
-
$3.02
Significant Holders of TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share (TXMD) as of Q3 2023
45 filings reported holding TXMD - TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share as of Q3 2023.
TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share (TXMD) has 37 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2.99M shares
of 11.5M outstanding shares and own 25.87% of the company stock.
Largest 10 shareholders include Rubric Capital Management LP (1.19M shares), Clearline Capital LP (455K shares), VANGUARD GROUP INC (385K shares), Tejara Capital Ltd (370K shares), BlackRock Inc. (137K shares), MORGAN STANLEY (133K shares), GEODE CAPITAL MANAGEMENT, LLC (84.8K shares), BRIDGEWAY CAPITAL MANAGEMENT, LLC (42K shares), GABELLI FUNDS LLC (31K shares), and STATE STREET CORP (30.1K shares).
This table shows the top 37 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.